

Unaudited financial statements

Statement of assets, liabilities, and partners' capital

September 30, 2025

Fotal assets	\$ 22,356,277
Capital contributions receivable	284,537
Escrow receivable	44,487
Interest receivable	23,524
Cash	214,959
Investments, at fair value (cost \$11,723,982)	\$ 21,788,770

Liabilities and partners' capital

Liabilities

Total liabilities	129,869
Accounts payable	800
Capital contributions received in advance	80,295
Accrued expenses	47,288
Audit	21,750
Tax	25,538
Due to related parties	\$ 1,486

Partners' capital

Total partners' capital	22,226,408
Total liabilities and partners' capital	\$ 22,356,277

Schedule of investments

September 30, 2025

Investments, at fair value	Invt. date	Shares (#) / Principal (\$)	Cost	Cost Fair value Unrealized gain (los		realized gain (loss)	Cos	t/share	Fair va	lue/share	
Ares Materials, Inc.											
Series A Preferred	06/27/2019	9,921,946	\$ 1,500,000	\$	2,637,253	\$	1,137,253	\$	0.15	\$	0.27
Biomakers, Inc.			1,101,155		2,609,727		1,508,572		_		_
Series A-1 Preferred	01/26/2024	876,451	1,000,000		2,508,572		1,508,572		1.14		2.86
Series A Preferred	12/09/2024	35,342	101,155		101,155		_		2.86		2.86
Compound Foods, Inc.			1,200,000		1,200,000		_		_		_
SAFE	09/27/2020	_	200,000		200,000		_		_		_
SAFE	03/25/2021	_	1,000,000		1,000,000		_		_		_
Cubbo Holdings Limited											
Series Seed-1 Preferred	11/08/2021	856,245	900,000		2,520,603		1,620,603		1.05		2.94
DProtein Inc.			200,000		200,000		_		_		_
SAFE	07/23/2021	_	100,000		100,000		_		_		_
SAFE	11/15/2022	_	20,000		20,000		_		_		_
SAFE	05/18/2023	_	80,000		80,000		_		_		_
Encellin, Inc.											
Series Seed-1 Preferred	06/28/2019	1,357,632	1,250,000		2,539,994		1,289,994		0.92		1.87
Equator Therapeutics, Inc.											
SAFE	12/14/2021	_	500,000		500,000		_		_		_
Fiado, Inc.			750,000		750,000		_		_		_
SAFE	08/03/2021	_	500,000		500,000		_		_		_
SAFE	10/29/2021	_	250,000		250,000		_		_		_

Schedule of investments (continued)

September 30, 2025

Investments, at fair value	Invt. date	Shares (#) / Principal (\$)	Cost	Fair value	U	nrealized gain (loss)	Cos	st/share	Fair value/share
Finless Foods Inc.			\$ 480,979	\$ 330,229	\$	(150,750)	\$	_	\$ _
Series A-3 Preferred	09/11/2020	336,020	245,093	94,343		(150,750)		0.73	0.28
Convertible Promissory Note	04/22/2024	235,886	235,886	235,886		_		_	_
GEn1E Lifesciences Inc.			1,000,000	5,061,864		4,061,864		_	_
Series Seed-3 Preferred	12/06/2022	520,724	500,000	1,998,070		1,498,070		0.96	3.84
Series Seed-4 Preferred	12/06/2022	798,466	500,000	3,063,794		2,563,794		0.63	3.84
Justo Inc.			889,635	876,888		(12,747)		_	_
Series A-9 Preferred	03/26/2021	66,607	42,655	29,908		(12,747)		0.64	0.45
Series C-1 Preferred	07/05/2024	538,939	241,995	241,995		_		0.45	0.45
Series C-2 Preferred	07/05/2024	1,347,348	604,985	604,985		_		0.45	0.45
Musa Technology Holding									
Series A-2 Preferred	09/30/2021	702,350	304,118	1,025,080		720,962		0.43	1.46
PRIXZ, INC.									
Series A-1 Preferred	04/15/2022	62,988	1,000,000	889,037		(110,963)		15.88	14.11
Torch Systems Inc.									
SAFE	11/10/2021	_	500,000	500,000		_		_	_
ZaxApp Holding Ltd.									
SAFE	12/22/2023		 148,095	148,095					
Total			\$ 11,723,982	\$ 21,788,770	\$	10,064,788			

Schedule of investments (continued)

September 30, 2025

The following table summarizes the investments by asset type:

Asset type	Cost	Fair value	Unrealized gain (loss)
Preferred stock	\$ 8,190,001	\$ 18,254,789	\$ 10,064,788
SAFEs	3,298,095	3,298,095	_
Convertible promissory note	235,886	235,886	_
Total	\$ 11,723,982	\$ 21,788,770	\$ 10,064,788

Statement of operations

Interest income	\$ 4,756
Total investment income	4,756
Expenses	
Management fees	130,122
Audit fees	7,250
Tax preparation fees	6,912
Fund administration fees	6,250
Total professional fees	20,412
Total expenses	150,534
Net investment loss	(145,778)
Net change in unrealized gain (loss) on investments	
Net change in unrealized gain on investments	2,298,855
Net gain on investments	2,298,855
Net increase in partners' capital from operations	\$ 2,153,077

Statement of changes in partners' capital

	General Partner	Limited Partners	Total
Partners' capital, beginning of period	\$ 760,534	\$ 19,312,796	\$ 20,073,330
Management fees	_	(130,122)	(130,122)
Net operating income (loss)	(509)	(15,146)	(15,655)
Net unrealized gain (loss)	74,830	2,224,025	2,298,855
Carried interest accrued	374,462	(374,462)	_
Partners' capital, end of period	\$ 1,209,317	\$ 21,017,091	\$ 22,226,408

Statement of cash flows

Net increase in partners' capital from operations	\$ 2,153,077
Adjustments to reconcile net increase in partners' capital from operations to net cash used in operating activities:	
Net change in unrealized gain on investments	(2,298,855)
Changes in operating assets and liabilities:	
Decrease in investment receivable	26,107
Increase in interest receivable	(4,757)
Decrease in escrow receivable	90,254
Increase in accrued expenses	14,163
Net cash used in operating activities	(20,011)
Cash flows from financing activities	
Capital contributions, net of change in capital contributions receivable	23,235
Net cash provided by financing activities	23,235
Net increase in cash	3,224
Cash, beginning of period	211,735
Cash, end of period	\$ 214,959